Market
Final acquisition price per share for Intra-Cellular Therapies?
2
Resolution / Starting Odds
$132 • 25%
Less than $132 • 25%
More than $132 • 25%
Deal not completed • 25%
Official press releases from Johnson & Johnson or Intra-Cellular Therapies, financial news outlets
Story
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion at $132 Per Share, Marking Largest Biotech Deal in Over a Year
Jan 13, 2025, 02:49 PM
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies Inc. for approximately $14.6 billion, marking the largest biotech deal in over a year. The acquisition, announced at the J.P. Morgan Healthcare Conference, involves a purchase price of $132 per share. Intra-Cellular, co-founded by Sharon Mates in 2002, is known for its drug Caplyta, which received FDA approval in December 2019. The deal comes amidst a flurry of biotech acquisitions, with Eli Lilly and GSK also announcing significant purchases of Scorpion Therapeutics and IDRx, respectively, during the same conference.
View original story
Similar markets
Increase by 10% to 20% • 25%
Decrease or no change • 25%
Increase by more than 20% • 25%
Increase by less than 10% • 25%
No acquisition announced • 25%
Less than $12 billion • 25%
$12 billion to $14 billion • 25%
More than $14 billion • 25%
Yes • 50%
No • 50%
No significant change • 25%
Decrease • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Acquisition Completed • 25%
Acquisition Abandoned • 25%
Acquisition Delayed • 25%
Other Outcomes • 25%
Acquisition delayed • 25%
Acquisition completed • 25%
No official outcome by end of 2025 • 25%
Acquisition abandoned • 25%
No change • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $24 • 25%
More than $25 • 25%
$24.26 to $25 • 25%
$24.25 • 25%